Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure
Status:
Not yet recruiting
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
Obese individuals have a higher prevalence of nocturnal hypertension and non-dipping blood
pressure (BP) and are associated with an increased risk of cardiovascular (CV) events and
death as compared with lean individuals. The Natriuretic Peptides (NPs) are hormones produced
by the heart which directly regulate BP by causing dilation of blood vessels and by removing
sodium and water from the body. NPs have a 24-hour day-night rhythm and controls the
day-night rhythm of BP as well. The NP-BP rhythm relationship is broken down in obese
individuals. Lower circulating levels of NPs, elevated renin hormone (a part of the
Renin-Angiotensin-Aldosterone System [RAAS]) at nighttime may also contribute to the high
nocturnal blood pressure in obese individuals and put them at a higher risk of developing CV
events. This current study seeks to determine the biological implications of
chronopharmacology for synchronizing NP-RAAS-based blood pressure therapy with the
physiological diurnal rhythms to restore the normal diurnal rhythm of blood pressure in obese
individuals.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Alabama at Birmingham
Treatments:
LCZ 696 Sacubitril and valsartan sodium hydrate drug combination Valsartan